Randomized, Controlled Study on Adjuvant Immunochemotherapy with PSK in Curatively Resected Colorectal Cancer
Authors: The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa): Toshio Mitomi, Shujii Tsuchiya, Noboru Iijima, Koichi Aso, Kaisuke Suzuki, Kiyoshi Nishiyama, Tomishige Amano, Toshitake Takahashi, Norihisa Murayama, Hisashi Oka, Kazumitsu Oya, Takashi Noto, and Nobuya Ogawa
Journal: Diseases of the Colon & Rectum
Study Design: Randomized, controlled trial
Participants: 448 patients with curatively resected colorectal cancer
Trial Length: 3-5 years
Intervention:
- Control group (n = 227): Mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) for over six months
- PSK group (n = 221): PSK orally for over three years, in addition to the same mitomycin C and 5-FU regimen as the control group
Primary Outcomes: Disease-free survival and overall survival
Summary: The study investigated the impact of adjuvant immunochemotherapy with PSK on disease-free survival and overall survival in patients with curatively resected colorectal cancer. The results demonstrated that the PSK group had significantly better disease-free survival (P = 0.0134) and overall survival (P = 0.0130) compared to the control group. The study suggests that adjuvant immunochemotherapy with PSK may be beneficial for patients with curatively resected colorectal cancer.
No responses yet